Boston Scientific notes JAMA article indicates Taxus stents superior to brachytherapy

By Lisa Kerner

Erie, Pa., March 15 - Boston Scientific Corp. said the Journal of the American Medical Association (JAMA) published results on the Taxus V ISR (in-stent restenosis) clinical trial that found the Taxus Express2 paclitaxel-eluting stent system achieved superior outcomes in the treatment of in-stent restenosis compared to those patients treated with radiation-based brachytherapy.

The study showed that compared with brachytherapy, implantation of paclitaxel-eluting stents reduced the nine-month rate of target vessel revascularization to 10.5% from 17.5%, and target lesion revascularization rate to 6.3% from 13.9%.

According to Boston Scientific, the study authors noted that the results from the trial, along with other studies, indicate that drug-eluting stents should now be considered the treatment of choice for most patients with ISR of previously implanted bare-metal stents.

The study included 396 patients at 37 sites in the United States and had a primary endpoint of nine-month target vessel revascularization.

Boston Scientific develops, manufactures and markets medical devices used in a broad range of interventional medical specialties. The company is located in Natick, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.